Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06212323 · ClinicalTrials.gov registry record

Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

A clinical trial of Smoldering Multiple Myeloma, sponsored by University of Utah.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT06212323 is a study of Smoldering Multiple Myeloma that is actively recruiting participants, run by University of Utah. The registered enrollment target is 100 participants, below the 795-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06212323, a study of Smoldering Multiple Myeloma, is actively recruiting participants, sponsored by University of Utah.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.

Interventions

  • OTHER Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.

Study Locations (1)

Utah

  • Huntsman Cancer Institute at the University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-01-11
Est. Completion 2030-03

Sponsor

University of Utah

818 total trials

What the Registry Record Tells You About NCT06212323

The ClinicalTrials.gov registry entry for NCT06212323 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 795-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (87% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI. is the first listed.

NCT06212323 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT06212323 about?

NCT06212323 is a clinical study titled "Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial". The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.

What is the current status of trial NCT06212323?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-01-11. Estimated completion is 2030-03.

What conditions does trial NCT06212323 study?

This clinical trial studies the following conditions: Smoldering Multiple Myeloma.

What interventions are being tested in trial NCT06212323?

The interventions under investigation include: Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI. (OTHER).

Who is sponsoring clinical trial NCT06212323?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06212323 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoldering Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.